Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1829P - In-hospital survival of metastatic patients admitted into medical intensive care units: A French nationwide study about 57,717 cases

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer in Special Situations/ Populations;  Supportive and Palliative Care

Tumour Site

Presenters

Nicolas Bertrand

Citation

Annals of Oncology (2021) 32 (suppl_5): S1237-S1256. 10.1016/annonc/annonc701

Authors

N. Bertrand1, D. Benoit1, A. Escande2, G. Ficheur3, S. Nseir4, A.S. Moreau4, E. Chazard3

Author affiliations

  • 1 Medical Oncology, CHU Lille, 59037 - Lille/FR
  • 2 Radiotherapy, Centre Oscar Lambret, 59000 - Lille/FR
  • 3 Cerim, CHU Lille, 59037 - Lille/FR
  • 4 Icu, CHU Lille, 59000 - Lille/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1829P

Background

Advances in oncology treatment led to longer survival in the metastatic setting. The relevance of transferring these patients into ICU (intensive care units) remains an ethical challenge, due to the burden of care required.

Methods

Cancer patients admitted into ICU from January 2008 to December 2014 were selected from the French nationwide hospital discharge summary database (called PMSI). Metastatic patients were defined as having an ICD10 code (International Classification of Diseases, 10th revision) of metastases (C78*-C79*) in the ICU stay or in the year before. We excluded patients under 18 years old, surgical stays (according to the French diagnoses related groups), and patients with hematological malignancies (C81*-C96*). For each patient, we only studied the first stay with ICU. Our primary endpoint was mortality rate during the ICU inpatient stay.

Results

We included 57,717 patients. The number of included patients gradually increased, from 7144 in 2008 to 9496 in 2014 (+4.7%/year in average). Most patients were men: 34938 (60.5%). Median age was 65.5 years (Q1-Q3: [57.4; 75.4]). The mean total length of stay was 17 days (SD=17.1). Regarding the cancer site, we notably observed 16582 cases of lung cancer (28.7%), 8744 cases of colorectal cancer (15.1%), and 5494 cases of breast cancer (9.1%). Overall, the in-hospital mortality was 32.7%, and was quite stable over time (from 31.6% in 2008 to 33.1% in 2014). The mortality rate varied depending on the cancer site: 18.0% for testicular, 23.0% for others, 23.3% for ovarian, 24.1% for endocrine, 24.9% for colorectal, 30.2% for breast, 30.2% for kidney, 30.6% for skin, 32.8% for female genital, 33.0% for prostatic, 33.3% for multiple, 34.1% for stomach, 37.2% for pancreatic, 37.9% for ear, nose and throat, 38.8% for lung, 40.1% for urinary, 40.5% for hepatobiliary, and 41.2% for esophageal. It increased with age, from 25.6% for 16-49 years old to 35.3% for those over 80.

Conclusions

In metastatic patients admitted in medical ICU, the overall mortality was higher than the general intra-hospital mortality in ICU in France (19%). Although the number of admissions increased, survival rates were quite stable.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.